Loading
Latest filing published 14 Jun 2021 for Biora Therapeutics, INC., €16.5M.
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Athyrium Capital Management, LP appears in our data through filings on Biora Therapeutics, Inc. shares, published by SEC (Form 4). We count 7 filings; the first trade dates from 23 June 2020 and the latest from 14 June 2021.
The open-market record is one-sided, with 5 purchases worth €74.8M and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2021: 3 purchases and no sales on the market.
The median purchase comes to €11.1M. 3 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. After 3 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -52.3%. They describe history only and say nothing certain about the share price ahead.
Most recently, on 14 June 2021, the filings show an open-market purchase worth €16.5M in Biora Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations